ArticleJournal of pain research2019
Pooled analysis of tanezumab efficacy and safety with subgroup analyses of phase III clinical trials in patients with osteoarthritis pain of the knee or hip.
Article in Journal of pain research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 9 registered trials, which are not on this map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A phase 3 randomized, double-blind, placebo-controlled multicenter study of the analgesic efficacy and safety of tanezumab in patients with osteoarthritis of the knee
A phase 3 randomized, double-blind, placebo-controlled multicenter study of the analgesic efficacy and safety of tanezumab in patients with osteoarthritis of the hip.
A phase 3, multi-center, randomized, double-blind, controlled study of the long-term analgesic efficacy and safety of tanezumab alone or in combination with non-steroidal anti-inflammatory drugs (nsaids) versus nsaids alone in patients with osteoarthritis of the knee or hip
A phase 3 randomized, double blind placebo and naproxen controlled multicenter study of the analgesic efficacy and safety of tanezumab in patients with osteoarthritis of the knee
A phase 3 randomized, double blind placebo and naproxen controlled multicenter study of the analgesic efficacy and safety of tanezumab in patients with osteoarthritis of the hip or knee
A phase 3 randomized, double-blind, placebo-controlled multicenter study of tanezumab on peripheral nerve function in patients with osteoarthritis.
A phase 3, randomized, double blind, controlled, multi center study of the analgesic efficacy and safety of tanezumab added on to diclofenac sr in patients with osteoarthritis of the knee or hip
A phase 3 randomized, double-blind, placebo and oxycodone controlled multi-center study of the efficacy and safety of tanezumab in patients with osteoarthritis of the knee or hip
A phase 3, randomized, double-blind, placebo-controlled, multicenter study of the analgesic efficacy and safety of subcutaneous administration of tanezumab in patients with osteoarthritis of the knee.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 50 citations in OpenAlex.
- Factors Contributing to Variability in Longitudinal Pain Scores in Osteoarthritis Randomised Clinical Trials: A Systematic Review and Meta-Analysis.European journal of pain (London, England) · 2026Pooled it
- Multimethod quantitative benefit-risk assessment of treatments for moderate-to-severe osteoarthritis.British journal of clinical pharmacology · 2022Pooled it
- The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Subcutaneous Administration of a Novel Anti-NGF Monoclonal Antibody (AK115) in Healthy Participants: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Phase I Clinical Trial.Drug design, development and therapy · 2025Trial
- Gender, age, disease severity, body mass index and diabetes may not affect response to subcutaneous tanezumab in patients with osteoarthritis after 16 weeks of treatment. A subgroup analysis of placebo-controlled trials.International journal of clinical practice · 2021Trial
- Efficiency and safety: comparison between preoperative analgesia and postoperative analgesia using non-steroidal anti-inflammatory drugs in patients receiving arthroscopic knee surgery in a multicenter, randomized, controlled study.Inflammopharmacology · 2021Trial
- Trial
- Peripheral neuronal sensitization and neurovascular remodelling in osteoarthritis pain.Nature reviews. Rheumatology · 2025Review
- Incorporating Multiple Imputation Into Tanezumab Dose-Response Modeling of WOMAC Pain CFB Across Six Randomized Placebo-Controlled Phase 3 Trials.CPT: pharmacometrics & systems pharmacology · 2025Article
- Article
- JAK-STAT Signaling and Beyond in the Pathogenesis of Spondyloarthritis and Their Clinical Significance.Current rheumatology reports · 2024Review
- Molecular pathogenesis of OA pain: Past, present, and future.Osteoarthritis and cartilage · 2024Review
- The potential role of synovial cells in the progression and treatment of osteoarthritis.Exploration (Beijing, China) · 2023Review
- Peripheral Nerve Safety of Nerve Growth Factor Inhibition by Tanezumab: Pooled Analyses of Phase III Clinical Studies in Over 5000 Patients with Osteoarthritis.Clinical drug investigation · 2023Article
- TrkA Co-Receptors: The Janus Face of TrkA?Cancers · 2023Review
- General Safety and Tolerability of Subcutaneous Tanezumab for Osteoarthritis: A Pooled Analysis of Three Randomized, Placebo-Controlled Trials.Arthritis care & research · 2022Article
- Osteoarthritis Pain.International journal of molecular sciences · 2022Review
- Based on minimal clinically important difference values, a moderate dose of tanezumab may be a better option for treating hip or knee osteoarthritis: a meta-analysis of randomized controlled trials.Therapeutic advances in musculoskeletal disease · 2022Article
- New developments in osteoarthritis pharmacological therapies.Rheumatology (Oxford, England) · 2021Review
- Nerve Growth Factor (NGF) Inhibitors and Related Agents for Chronic Musculoskeletal Pain: A Comprehensive Review.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2021Review
- Monoclonal Antibodies for Chronic Pain Treatment: Present and Future.International journal of molecular sciences · 2021Review
Corrections and comments
- Erratum issued
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeA pooled analysis was conducted to evaluate tanezumab efficacy and safety in patients with osteoarthritis (OA), including subgroup analyses of at-risk patients with diabetes, severe OA symptoms, and those aged ≥65 years. PATIENTS AND
methodsData from phase III placebo-controlled clinical trials of patients with moderate-to-severe OA of the knee or hip were pooled to evaluate tanezumab efficacy (four trials) and safety (nine trials). Patients received intravenous tanezumab, tanezumab plus an oral NSAID (naproxen, celecoxib, or diclofenac), active comparator (naproxen, celecoxib, diclofenac, or oxycodone), or placebo. Efficacy assessments included change from baseline to week 16 in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain and physical function scores, Patient's Global Assessment (PGA) of OA, and percentage of patients with ≥30%, ≥50%, ≥70%, and ≥90% improvement in WOMAC pain. Safety assessments included adverse event (AE) documentation and physical and neurologic examinations.
resultsTanezumab significantly improved all efficacy end points in the overall population. Efficacy in at-risk patient subgroups was similar to the overall population. Incidence of AEs was highest in the tanezumab plus NSAID group and lowest in the placebo group. Incidence of AEs in the tanezumab monotherapy and active comparator groups was similar. Overall incidence of AEs was similar across subgroups. AEs of abnormal peripheral sensation were more frequently reported in tanezumab-treated patients compared with placebo or active comparator. Patients receiving active comparator had a slightly higher incidence of AEs suggestive of postganglionic sympathetic dysfunction.
conclusionTanezumab consistently provided significant improvement of pain, physical function, and PGA in individuals with OA, including patients with diabetes, severe OA symptoms, or aged ≥65 years. No increased safety risk was observed in at-risk patient subgroups.
trial registrationNCT00733902, NCT00744471, NCT00830063, NCT00863304, NCT00809354, NCT00864097, NCT00863772, NCT01089725, NCT00985621.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.